[Edaily Reporter KIM JI-WAN ] Geninus ( GENINUS Inc.(389030)) announced on the 30th that it had successfully concluded discussions on technology transfer and business development with global pharmaceutical companies at the “Bio International Convention” (hereinafter “Bio USA”), the world’s largest biotech event.

Although GENINUS Inc. participated officially in Bio USA for the first time this year, it secured meetings with six global big pharma companies prior to the conference, demonstrating the industry’s high level of interest in its platform technology.

Chief Business Development Officer (CBO) Kim Jae-won, who has experience in global technology transfer, and Chief Technology Officer (CTO) Noh Hae-sung, an expert in new drug development, attended the event in person to explain the company’s platform competitiveness and commercialization strategies to global pharmaceutical companies.

The company assessed the event as a crucial opportunity to showcase its position and presence on the global stage as a platform-based new drug development company.

The core asset that GENINUS Inc. highlighted at Bio USA was “IntelliRVL,” its proprietary “first-in-class” target discovery platform.

IntelliRVL is an integrated platform that combines vast clinical genomic data with advanced artificial intelligence (AI) algorithms. It is designed to precisely analyze the tumor microenvironment (TME)—particularly in cases where tumors do not respond to existing anticancer therapies or have developed resistance—to uncover underlying mechanisms and rapidly and accurately identify innovative drug targets.

Recently, securing innovative drug targets has emerged as a key competitive advantage for future growth in the global pharmaceutical industry. As the market for next-generation anticancer modalities—such as ADCs (antibody-drug conjugates) and TCEs (next-generation T-cell engagers)—grows rapidly, demand for new targets continues to expand.

During this partnering session, GENINUS Inc. held in-depth business meetings with numerous pharmaceutical companies and biotech firms, including six global big pharma companies. In these discussions, the company highlighted the technical differentiation and scalability of “Intellibil,” while also engaging in broad discussions with ADC- and TCE-based drug development companies regarding potential joint research, target validation, and technology transfer.

The industry highly values GENINUS Inc.’s competitiveness, noting that few companies possess both proprietary cancer genomic data and an AI-based analysis platform. In particular, since proactively securing promising targets in the early stages of new drug development can lead to large-scale technology transfer and commercialization achievements in the future, global demand for AI-based target discovery platforms is expected to grow even further.

GENINUS Inc. official stated, “Intellibil is not merely a genomic data analysis platform, but a platform capable of identifying innovative new drug targets with actual clinical efficacy and commercialization potential,” adding, “At this year’s Bio USA, global big pharma companies showed great interest in our competitive edge, which stems from our simultaneous possession of both data and an AI platform.”

The representative added, “Based on the positive response we received on-site, we plan to actively pursue follow-up discussions and strengthen our business development activities to secure global joint research and technology transfer opportunities.”

Meanwhile, Bio USA is the world’s largest biotech industry event, attended by pharmaceutical and biotech companies and investment institutions from around the globe. It is regarded as a premier networking event for the global biotech industry, with tens of thousands of industry professionals attending each year to discuss technology transfer, joint research, investment attraction, and strategic partnerships.